RxDoctor Payments Data

David Henzler, MD

Neurology · Anchorage, AKNPI 1063588184

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 257 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations.

$5,781in general payments, 2019–2025

Across 257 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$654
  • Biogen$525
  • Eisai Inc.$420
  • Argenx US, Inc.$379
  • Novartis$347
  • AbbVie$337
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$5,72899%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,781 in reported general payments places this provider in the 65th percentile of 21 neurology providers in Alaska.

See all neurology providers in Alaska

Medicare billing

Part B allowed, 2024
$52,799
Medicare patients
127
Services billed
933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate21$43,507
NuedextaDextromethorphan Hbr/Quinidine27$19,758
RytaryCarbidopa/Levodopa12$12,667
Lamotrigine ErLamotrigine16$10,864
Emgality PenGalcanezumab-Gnlm12$8,171
Carbidopa-LevodopaCarbidopa/Levodopa47$1,848
Carbamazepine ErCarbamazepine28$1,809
Memantine Hcl48$1,377
Lacosamide37$1,226
Levetiracetam59$1,128
Divalproex Sodium67$855
Levetiracetam ErLevetiracetam15$664
Zonisamide28$634
Donepezil Hcl52$626
Lamotrigine34$572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$144$43,50721 claims
Amneal Pharmaceuticals LLCRytary$35$12,66712 claims
Upsher-smith Laboratories LLCTopiramate$33$31321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 21 neurology providers in Alaska.

Other neurology in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →